Stockholders Approve Amended Incentive Plan, Increasing Share Reserve by 962,000 Shares
ANIP sits 46% above its 52-week low of $56.71.
Summary
ANI Pharmaceuticals' stockholders approved an amended stock incentive plan, adding 962,000 shares to the equity compensation pool, which could lead to substantial future dilution.
Key Events · Financing and Capital Events · ANIP
-
Amended Stock Incentive Plan Approved
Stockholders approved the Amended and Restated 2022 Stock Incentive Plan at the Annual Meeting on May 21, 2026.
-
Significant Increase in Share Reserve
The plan's aggregate share reserve was increased by 962,000 shares, bringing the new total to 8,222,000 shares available for future equity awards.
-
Substantial Potential Dilution
The newly authorized 962,000 shares represent approximately 4.2% of the company's current outstanding common stock. The total share reserve of 8,222,000 shares for the plan represents over 36% of outstanding shares, indicating a very substantial potential for future dilution.
-
Routine Governance Matters Approved
Stockholders also re-elected all seven director nominees, ratified Ernst & Young LLP as the independent auditor, and approved executive compensation on an advisory basis, with future advisory votes to be held annually.
Analysis · ANIP · Life Sciences
Stockholders approved an amendment to the 2022 Stock Incentive Plan, increasing the total shares available for equity awards by 962,000 to 8,222,000 shares. This expansion of the equity compensation pool, representing approximately 4.2% of current outstanding shares, provides the company with more flexibility to attract and retain talent but also introduces significant potential future dilution for existing shareholders. The total authorized pool for the plan now represents over 36% of outstanding shares.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 29.9% of the 1656 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ANIP was trading at $82.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $56.71 to $99.50. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.